Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc., a leader in immunotherapy for cancer treatment, has announced participation in upcoming September investment conferences with its CFO and CMO engaging in fireside chats at the H.C. Wainwright and Cantor Global Healthcare conferences respectively. The company, known for its promising cancer therapeutic agent pelareorep, will also conduct one-on-one investor meetings and provide webcasts of their presentations. Oncolytics continues to focus on advancing pelareorep in clinical trials for metastatic breast and pancreatic cancers, both of which have received Fast Track designation by the FDA.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
